Uranium doesn’t often grab headlines, but behind the scenes, a bull market is quietly building.
According to Citi, the conditions are in place for a sustained rally, with prices forecast to hit $100 per pound by 2026.
Noble Capital Markets analysts have highlighted MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF)’s growing commercial traction following the company’s second quarter results.
The analysts pointed to the early success of MustGrow’s TerraSante biofungicide, which sold out in the US during Q2 2025, and identified the product as a key driver of improved gross margins.
Ocean Power Technologies Inc (NYSE-A:OPTT) (OPT) announced it is shipping two WAM-V Unmanned Surface Vehicles (USV) to Remah International Group, a privately held company headquartered in the United Arab Emirates (UAE) with a focus on military services.
OPT said it is planning to expand its presence in the region with the establishment of a sales and operations office and related strategic hires.
Medicus Pharma (NASDAQ:MDCX) reported that it has completed its previously announced acquisition of Antev Limited, a UK-based clinical-stage drug development company.
Medicus said it has acquired 98.6% of the issued and outstanding shares of Antev for total consideration of about US$2.97 million in cash plus 1,603,164 common shares of Medicus.
Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on viral immunotherapies, announced the appointment of Dr Carl June to its Research Advisory Board.
Dr June is an internationally recognized leader in cancer immunotherapy and played a key role in developing the first FDA-approved CAR-T cell therapy.
Digi Power X Inc (NASDAQ:DGXX, TSX-V:DGX) reported that it increased its digital asset holdings during August and provided an update on its strategic shift toward artificial intelligence (AI) infrastructure, including construction at its Alabama site.
The energy infrastructure company increased its Bitcoin holdings 37% over the previous month to 85 Bitcoin, while Ethereum holdings nearly doubled to 1,000 Ethereum, valued at $4.4 million.
G Mining Ventures Corp (TSX:GMIN, OTCQX:GMINF) reported that it has received the Environmental Permit from Guyana's Environmental Protection Agency (EPA) for the Oko West Gold Project.
The mining company, which owns projects in Brazil and Guyana, said the five-year permit, valid through July 2030, authorizes the construction and operation of Oko West, which is expected to create an average of 1,270 direct permanent jobs during its lifetime.
Meren Energy Inc (TSX:MER, OTC:AOIFF) has announced several changes to its executive leadership team as part of an organizational streamlining initiative.
The company said Craig Knight has stepped down from his role as chief operating officer to return to Australia for personal reasons. Knight will remain with Meren until October 31 to support the transition.
Arizona Gold & Silver Inc (TSX-V:AZS, OTCQB:AZASF) announced that it has increased the size of its previously announced non-brokered private placement following strong investor demand.
The offering has been upsized from 3,333,333 units to 6,666,666 units, priced at C$0.30 per unit, for total gross proceeds of C$2 million.
Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF) announced its unaudited financial and operating results for the first quarter 2026, in which the company achieved its highest ever gross margins of 90%, compared with 74% during the same period last year.
The diversified spatial computing company also reported significantly reduced operating expenses, and a narrower net loss compared to the same period in 2025, reflecting continued progress toward sustainable profitability.
Shares in Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF) jumped 40% on Tuesday after the company revealed encouraging new drill results from its Mushima North project in Zambia, confirming the extension of a promising silver discovery.
The latest drilling at Target A1 has pushed the known mineralised zone 225 metres further north, with some of the highest silver and copper grades seen at the site to date.
Shares in Tialis Essential IT (LSE:TIA) surged 36% on Tuesday after the company announced a major contract extension worth approximately £50 million with a long-standing client.
The five-year agreement significantly expands Tialis’s existing work with the customer and will see the AIM-listed managed services group provide a range of support services, including Lifecycle Services, Tech Bars, End User Support and Field Engineering.
Pulsar Helium Inc (AIM:PLSR, TSX-V:PLSR, OTCQB:PSRHF) announced the signing of an agreement to acquire Quantum Hydrogen Inc, which holds rights to 59,100 acres in Minnesota west of the firm's Topaz helium project.
The agreement, currently a non-binding term sheet, would increase Pulsar’s land position in Minnesota by about 1,000%, and, Pulsar noted that the acreage is considered prospective for helium and hydrogen, and has geological similarities to Topa
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) has struck a deal to sell its royalty interest in the Dugbe gold project in Liberia for up to $20 million, as it continues to streamline its portfolio and focus on higher-priority assets.
The sale involves a wholly-owned subsidiary of Ecora that holds a 2% net smelter return (NSR) royalty over the development project.
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) has updated on continuing preparations for the Tulu Kapi gold project in Ethiopia.
Approvals and signing of the full finance package are targeted for September.
Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF) has extended a promising silver discovery at its Mushima North project in Zambia, after drilling confirmed that thick seams of mineralisation continue at least 225 metres further north than previously thought.
The company, which is listed on London’s junior AIM market, said the latest drill results from its Target A1 prospect included the highest grades of silver and copper recorded so far at the site.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has activated its first Hong Kong clinical site at Queen Mary Hospital, enabling patient enrolment for the Phase 1 trial of RC220 in combination with doxorubicin in advanced solid tumours. Screening has commenced, with the first Hong Kong patient expected to begin treatment this month.
The Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of RC220, as well as determine the maximum tolerated combined dose with doxorubicin. Prince of Wales Hospital in Hong Kong has also secured ethics and regulatory approvals, with site activation scheduled in the coming weeks. This will establish a second Hong Kong recruitment site.